Abstract:
The present invention provides for a method to prevent accelerated atherosclerosis in a subject predisposed thereto which comprises administering to the subject a polypeptide derived from soluble receptor for advanced glycation endproduct in an amount effective to prevent accelerated atherosclerosis in the subject. The present invention also provides for a method to prevent a macrovessel disease in a subject predisposed thereto which comprises administering to the subject a polypeptide derived from soluble receptor for advanced glycation endproduct in an amount effective to prevent macrovessel disease in the subject.
Abstract:
Fluorescently marked targets bind to a substrate 230 synthesized with polymer sequences at known locations. The targets are detected by exposing selected regions of the substrate 230 to light from a light source 100 and detecting the photons from the light fluoresced therefrom, and repeating the steps of exposure and detection until the substrate 230 is completely examined. The resulting data can be used to determine binding affinity of the targets to specific polymer sequences.
Abstract:
Disclosed are RAGE fusion proteins comprising RAGE polypeptide sequences linked to a second, non-RAGE polypeptide. The RAGE fusion protein may utilize a RAGE polypeptide domain comprising a RAGE ligand binding site and an interdomain linker directly linked to an immunoglobulin CH2 domain. Such fusion proteins may provide specific, high affinity binding to RAGE ligands. Also disclosed is the use of the RAGE fusion proteins as therapeutics for RAGE-mediated pathologies.
Abstract:
There is provided a catalyst composition having improved hydrothermal stability for the catalytic cracking of a hydrocarbon feedstock to selectively produce propylene. The catalyst composition comprises a first crystalline molecular sieve selected from the group consisting of IM-5, MWW, ITH, FER, MFS, AEL, and AFO and an effective amount of a stabilization metal (copper, zirconium, or mixtures thereof) exchanged into the molecular sieve. The catalyst finds application in the cracking of naphtha and heavy hydrocarbon feedstocks. When used in the catalytic cracking of heavier hydrocarbon feedstocks, the catalyst composition preferably comprises a second molecular sieve having a pore size that is greater than the pore size of the first molecular sieve. The process is carried out by contacting a feedstock containing hydrocarbons having at least 4 carbon atoms is contacted, under catalytic cracking conditions, with the catalyst composition.
Abstract:
An improved optical photolithography system and method provides predetermined light patterns generated by a direct write system without the use of photomasks. The Direct Write System provides predetermined light patterns projected on the surface of a substrate (e.g., a wafer) by using a computer controlled means for dynamically generating the predetermined light pattern, e.g., a spatial light modulator. Image patterns are stored in a computer and through electronic control of the spatial light modulator directly illuminate the wafer to define a portion of the polymer array, rather than being defined by a pattern on a photomask. Thus, in the Direct Write System each pixel is illuminated with an optical beam of suitable intensity and the imaging (printing) of an individual feature is determined by computer control of the spatial light modulator at each photolithographic step without the use of a photomask. The Direct Write System including a spatial light modulator is particularly useful in the synthesis of DNA arrays and provides an efficient means for polymer array synthesis by using spatial light modulators to generate a predetermined light pattern that defines the image patterns of a polymer array to be deprotected.
Abstract:
A process for the isomerization of xylenes and the conversion of ethylbenzene to benzene and ethane using a catalyst system comprising two catalysts. The first catalyst is unselectivated and comprises: (a) an intermediate pore size zeolite, e.g., ZSM-5; (b) at least one hydrogenation component to deethylate ethylbenzene, e.g. Group VIII and/or Group VIIIB metal; and (c) an amorphous binder, said first catalyst requiring at least 50 minutes to sorb 30% of the equilibrium capacity of ortho-xylene at 120° C. and at an ortho-xylene partial pressure of 4.5±0.8 mm of mercury. The second catalyst comprises an intermediate pore size zeolite, e.g., ZSM-5, and requires less than 50 minutes to sorb 30% of the equilibrium capacity of ortho-xylene at 120° C. and at an ortho-xylene partial pressure of 4.5±0.8 mm of mercury. The amount of first catalyst present in the catalyst system is a volume greater than 55 percent based on the sum of the volumes of the first catalyst and second catalyst.
Abstract:
The present method provides for an isolated peptide having an amino acid sequence corresponding to the amino acid sequence of a V-domain of a receptor for advanced glycation endproduct (RAGE). The present invention also provides for an isolated peptide having an amino acid sequence A-Q-N-I-T-A-R-I-G-E-P-L-V-L-K-C-K-G-A-P-K-K-P-P-Q-R-L-E-W-K (SEQ. ID No: 1). The present invention provides for a pharmaceutical composition comprising a therapeutically effect amount of an isolated peptide having an amino acid sequence corresponding to the amino acid sequence of a V-domain of RAGE. The present invention also provides for a method for inhibiting interaction of an amyloid-&bgr; peptide with a receptor for advanced glycation end product which is on the surface of a cell, which comprises contacting the cell with the peptide or a functionally equivalent agent, wherein the peptide or agent is capable of inhibiting interaction of the amyloid-&bgr; peptide with the receptor for advanced glycation end product, and the peptide or agent is present in an amount effective to inhibit interaction of the amyloid-&bgr; peptide with the receptor for advanced glycation endproduct.
Abstract translation:本方法提供了具有对应于晚期糖基化终产物(RAGE)受体的V-结构域的氨基酸序列的氨基酸序列的分离的肽。 本发明还提供具有氨基酸序列A-Q-N-I-T-A-R-I-G-E-P-L-V-L-K-C-K-G-A-P-K-P-P-Q-R-L-E-W-K(SEQ ID NO:1)的分离肽。 本发明提供了一种药物组合物,其包含治疗有效量的具有对应于RAGE的V-结构域的氨基酸序列的氨基酸序列的分离的肽。 本发明还提供了抑制淀粉样蛋白-β肽与细胞表面上的晚期糖基化终产物的受体的相互作用的方法,其包括使细胞与肽或功能等同试剂接触,其中 肽或试剂能够抑制淀粉样蛋白β肽与晚期糖基化终产物的受体的相互作用,并且肽或试剂以有效抑制淀粉样蛋白-β肽与晚期糖基化终产物受体相互作用的量存在 。
Abstract:
The present invention provides for a method for treating an ischemic disorder in a subject which comprises administering to the subject a pharmaceutically acceptable Factor IXa compound in a sufficient amount over a sufficient time period so as to treat the ischemic disorder in the subject. The invention further provides a method for treating an ischemic disorder in a subject which comprises administering to the subject a pharmaceutically acceptable form of inactivated Factor IXa in a sufficient amount over a sufficient period of time to inhibit coagulation so as to treat the ischemic disorder in the subject.
Abstract:
A wireless sensor for indicating a physical state within an environment includes a housing defining a hermetically sealed cavity. A structure located within the cavity of the housing has elements providing capacitance, the elements being arranged such that the distance and thereby the capacitance of the structure changes when a physical state of the environment changes. The structure has a resonant frequency based at least in part on the capacitance of the structure when in the presence of a fluctuating electromagnetic field. When the sensor is positioned within an environment and is subjected to a fluctuating electromagnetic field, the resonant frequency indicates the physical state of the environment.